

DT16 Rec'd PCT/PTO 2 1 APR 2003

**PATENT** 

Attorney Docket No. 218811 DHHS Reference E-025-1999/0-US-03

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Goldman et al.

RECEIVED

Application No. 10/089,009

MAY 0 9 2003

Filing Date: August 6, 2002

**TECH CENTER 1600/2900** 

For: INTERLEUKIN-2 RECEPTOR ASSOCIATED POLYPEPTIDES

## REQUEST FOR CORRECTED FILING RECEIPT

U.S. Patent and Trademark Office Application Processing Division Customer Correction Branch Washington, DC 20231

Dear Sir:

Applicants respectfully request that a corrected version of the Official Filing Receipt (copy enclosed) be issued for the above-identified patent application.

Under "TITLE," which reads:

Interluekin-2 receptor associated polypeptides

it should read:

### Interleukin-2 receptor associated polypeptides

Please enter this correction as noted on the enclosed copy of the Official Filing Receipt.

## **CERTIFICATE OF MAILING**

I hereby certify that this REQUEST FOR CORRECTED FILING RECEIPT (along with any documents referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231.

april 15, 2003

Ellen K. Manl

In re Appln of Goldman et al. U.S. Patent Appln. No. 10/089,009

Respectfully/submitted,

Carol Larcher, Reg. No. 35,243

One of the Attorneys for Applicants

LEYDIG, VOIT & MAYER, LTD.

Two Prudential Plaza, Suite 4900


180 North Stetson

Chicago, Illinois 60601-6780


(312) 616-5600 (telephone)

(312) 616-5700 (facsimile)

Date: April 15, 2003







Commissioner for Patents Washington, DC 20231 www.uspto.gov

 APPLICATION NUMBER
 FILING DATE
 GRP ART UNIT
 FIL FEE REC'D
 ATTY.DOCKET.NO
 DRAWINGS
 TOT CLAIMS
 IND CLAIMS

 10/089,009
 08/06/2002
 1653
 1194
 NIH-05111
 6
 21
 7

**CONFIRMATION NO. 5287** 

23460 LEYDIG VOIT & MAYER, LTD TWO PRUDENTIAL PLAZA, SUITE 4900 180 NORTH STETSON AVENUE CHICAGO, IL 60601-6780 FILING RECEIPT

\*OC000000009723329\*

Date Mailed: 04/02/2003

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Carolyn K. Goldman, Rockville, MD; Neil Goldman, Rockville, MD; Thomas A Waldmann, Silver Spring, MD; LEYING, VOIT & MAYER RECEIVED

APR 1 4 2003

PAT/TM One Date /

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/US00/25963 09/21/2000 which claims benefit of 60/155,968 09/24/1999

RECEIVED

MAY 0 9 2003

Foreign Applications

**TECH CENTER 1600/29**(

Projected Publication Date: None, application is not eligible for pre-grant publication

LAH

Non-Publication Request: No

Early Publication Request: No

Title

Interleukin - 2 receptor associated polypeptides Interluekin-2 receptor associated polypeptides

**Preliminary Class** 

# LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

#### **GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

#### **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).